|
|
|
|
Resistance to HER2-targeted therapy
|
|
|
|
|
|
|
|
نویسنده
|
Valadan Reza ,Rafiei Alireza ,Tehrani Mohsen ,Nejatollahi Forough
|
|
منبع
|
research in molecular medicine - 2013 - دوره : 1 - شماره : 1 - صفحه:1 -9
|
|
چکیده
|
Production and approval of trastuzumab (herceptin®) for the treatment ofmetastatic breast cancer (mbc) was a millstone in antibody-based targetedtherapy in the cancer treatment. however, despite the early success in the clinicaltrials, trastuzumab failed to appreciate the initial attraction due to development ofresistance to the drug. majority of patients who benefit from the drug acquireresistance to it and experience tumor recurrence within 1 year. several molecularand cellular mechanisms underlying the resistance to trastuzumab have beenproposed. in this review, first, we provide a brief history leading to production oftrastuzumab. also we consider the cellular and molecular antitumor effects oftrastuzumab and then, we discuss the mechanisms underlying trastuzumabresistance in four levels.
|
|
کلیدواژه
|
Trastuzumab ,ErbB ,Breast cancer ,Mechanisms of action ,Resistance
|
|
آدرس
|
mazandaran university of medical sciences, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, ایران, mazandaran university of medical sciences, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, ایران, mazandaran university of medical sciences, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, ایران, shiraz university of medical sciences, Recombinant antibody laboratory, Department of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, ایران
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|